Immunome’s Phase III Varegacestat Data Show Best-In-Class Potential In Desmoid Tumors

Filing Planned For Q2 2026

 
• By Mandy Jackson
  
Phase III results for varegacestat support a planned NDA filing in Q2 of 2026 (Shutterstock)

More from Clinical Trials

More from R&D